About Event

Welcome to the Definitive Industry Forum for Spearheading Cellular Therapies for Autoimmune Indications

Join industry trailblazers to seize novel opportunities at the 2nd Cell Therapy for Autoimmune Disease Summit as the only meeting focused on developing safe, efficacious, affordable, and curative cell-based therapies for autoimmune patients to transform their treatment!

Get involved in this unmissable summit to learn and connect with pioneers including Cartesian Therapeutics, the University of Pennsylvania, Bristol Myers Squibb, Novartis, and many more to troubleshoot safety concerns, showcase clinical advancements, understand long-term effects in autoimmune patients, and much more.

Whether your team is ahead of the curve and currently pursuing this approach, or if you are looking to gain deeper insights into this field to advance your current pipelines, this cutting-edge conference was designed to inspire and facilitate the brainstorming of best-in-class approaches for developing more effective cell-based treatment solutions for patients affected by autoimmune conditions.

2nd Cell Therapy for Autoimmune Diseases Summit What's New Banner
Workshop A will assess current & future opportunities in bringing cell therapies to the autoimmune space.
Join industry trailblazers. Workshop B will outline key considerations for successful cell therapy trials for autoimmune patients.

Attend the 2nd Cell Therapy for Autoimmune Disease Summit to:

1

Uncover the latest clinical results showcasing evidence of the benefit of cell therapies for autoimmune indications with BMS, Cabaletta Bio, and Quell Therapeutics.

2

Accelerate entry into the clinic through an understanding of preclinical results with Abata Therapeutics, Intellia Therapeutics, and Cincinnati Children’s Hospital Medical Center.

3

Optimize engineering of advanced cell therapies for stronger efficacy, potency, and reliable remission with Gentibio, Appia Bio, and Synaptimmune.

4

Lead the exploration of the long-term effects of cell therapies in autoimmune patients and the mechanisms behind these effects with iCell Gene, University of Tennessee and UT Health San Antonio.

5

Explore regulatory CMC and safety expectations when entering the autoimmune space with the Association for the Advancement of Blood & Biotherapies, Cartesian Therapeutics and IASO Biotherapeutics.

Who Will You Meet?

Connect with top cell therapy pioneers, clinicians, investors, and wavemakers who share a focus on accelerating this approach for autoimmune patients to realize a curative treatment.

This graph demonstrates the seniority of attendees, with 16% being Chief/CXO level, 15% being Presidents/VPs, 35% being directors, 5% being heads, 3% being managers, 4% being professors, 9% being scientists, and 16% having other job titles. These statistics were taken from attendees of the 2023 summit. Join these industry trailblazers in 2024.
Companies Attended 2023, with 37% being drug developers, 19% being consultants, 15% being equipment and service providers, 8% being research institutes and the remaining 15% having other job titles. These statistics were taken from the 2023 summit.
Allogene Therapeutics Logo

“Good mix of clinical, research, and commercial topics led by leaders in the field with presence of the most relevant companies that are likely to generate the next wave of exciting clinical data in this space.” 

Executive Director, Allogene Therapeutics, 2023 Attendee